Cassette dosing of compounds for preclinical drug plasma pharmacokinetic analysis has been shown to be a powerful strategy within the pharmaceutical industry for increasing throughput while decreasing the number of animals used. Presented here for the first time is data on the application of a cassette dosing strategy for label-free tissue distribution studies. The aim of the study was to image the spatial distribution of eight non-proprietary drugs (haloperidol, bufuralol, midazolam, clozapine, terfenadine, erlotinib, olanzapine and moxifloxacin) in multiple tissues after oral and intravenous cassette dosing (4 compounds per dose route). An array of mass spectrometry imaging technologies, including matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI MSI), liquid extraction surface analysis (LESA-MS/MS) and desorption electrospray ionization (DESI-MS) was used. Tissue analysis following intravenous and oral administration of discretely and cassette-dosed compounds demonstrated similar relative abundances across a range of tissues indicating that a cassette dosing approach was applicable.
Introduction
The development of mass spectrometric analytical technologies has enabled pharmaceutical research and development to employ an increasingly wide array of high-throughput screening modalities. Compound optimization with early, parallel elucidation of the physiochemical and pharmacokinetic properties enables a broader choice of compound leads from which candidate drugs can be selected and has also been shown to reduce compound attrition in development [1] .
The simultaneous dosing of drugs during in vivo research is typically termed cassette dosing (though also referred to as N-in-one dosing). Cassette dosing was first employed by pharmaceutical companies towards the end of the 1990's, when simultaneous measurements of five compounds were made during the development of potential therapeutics for the treatment of benign prostatic hyperplasia [2] . Cassette dosing and analysis has been shown to be applicable for both orally [3] and intravenously [4] administered drugs. Factors that need to be considered when devising a cassette dosing experiment include: mass spectrometry instrumentation and LC requirements (positive or negative mode ionization); if drugs or their metabolites are likely to have common structures or fragmentation patterns; if compounds require specific formulation (solubility at specific pH) and careful attention should be given to the dose levels selected. While such factors can be mitigated for by the selection of appropriate combinations of compounds to be analyzed, there remains a risk of drug-drug interactions during in vivo administration. This topic is extensively discussed in several reviews on cassette dosing [5] [6] [7] . Interactions mainly arise around competition at clearance pathways. Other reported interactions including heteroactivation of clearance pathways, which is the activation of a metabolic enzyme by a second drug acting through an allosteric mechanism (acting on a site other than the active site). There is also the chance of pharmacological and toxicological effects on organ blood flows and clearances [7] .
However, during early drug discovery, the advantage of parallel preliminary experiments means that the risk of erroneous results from drug-drug interactions is outweighed by the saving in reduced time and cost, as non-cassette experiments will always be performed on compounds that are to be progressed later in the discovery pipeline.
Traditionally discovery phase pharmacokinetic analysis has been performed using sensitive triple quadrupole mass spectrometers, usually in combination with rapid chromatography systems and operated with automated or semi automated optimization software [8] . This generic approach enables rapid quantification of chemically diverse compounds from biofluids or tissue homogenates. Whilst these methods are ideally suited for deriving pharmacokinetic parameters from homogeneous biofluids, they are less suitable to analysis of heterogeneous tissue samples. Furthermore, any tissue information from homogenates can be misleading due to factors such as residual blood concentration or dilution. Compound biodistribution information is usually collected at a later stage in a compounds life-cycle using techniques like quantitative whole body auto-radiography (qWBA) [9] . Such analysis retains distribution information lost during homogenization but have major limitations such as the need for a radiolabelled compound, rendering the technique impractical for discovery use. Label based techniques are also limited in their inability to distinguish a parent compound from any metabolites that still contain the label, hence producing an ambiguous representation of a compounds distribution.
Mass spectrometry imaging (MSI) [10, 11] , regarded as collection of multiple mass spectra by rastering across a tissue section in two dimensions and mass spectrometry profiling (MSP) [12] [13] [14] [15] , generally regarded as collection of mass spectra at discrete points on a tissue section, have recently emerged as technologies that have the capability to obtain label-free compound biodistribution, relative abundance and quantitation data by analyzing tissue sections directly.
Such methods enable the simultaneous analysis of drugs, metabolites, endogenous small molecules, lipids and peptides directly from tissue sections. Several comprehensive reviews describe methodologies [16] [17] [18] utilizing a range of sample ionization methods. Matrix assisted laser desorption ionization (MALDI) is arguably the most effective for pharmaceutical research and is most commonly employed for MSI. However, alternative ionization methods such as desorption electrospray ionization (DESI) are amenable for use in MSI [25] . Techniques like liquid extraction surface analysis (LESA) can be used to increase the sensitivity of tissue analysis when target compounds cannot be detected by other MSI ionization methods but their use to date has been restricted to low spatial tissue profiling at only a few sampling positions across a tissue section [13] . While the origins of LESA and DESI can both be traced back to electrospray ionization they exhibit different but complementary strengths and weaknesses. LESA can have high sensitivity when used in selected reaction monitoring mode on a triple quadrupole MS but lacks the high spatial resolution that DESI is capable of providing. DESI in contrast can supply structure rich MS images (figure 1-DESI endogenous masses, showing multiplex analysis within the cassette dosed sections) at high spatial resolution (~ 50 µm) [25] , but has less apparent sensitivity due to the decrease in sampling area.
The utility of MSI is determined by the ability to detect the target compound at the level present in the sample and is determined by a number of factors such as the ionization efficiency and localized suppression caused by salts and endogenous compounds within the tissues. There is also a risk that the mass of the target compound is masked in the mass spectrum by endogenous 6 compounds or MALDI matrix adduct signal. Therefore 'upfront' MSI ionization assessments are routinely performed to detect target compound in tissue samples before undertaking extensive studies. The risk of failing to detect a target in a sample can be further mitigated by using the orthogonal MSI techniques previously alluded to, such as LESA and DESI, which are becoming increasingly popular as imaging tools. These ionization techniques are essentially based on generic nano-electrospray ionization and can be used to cover a much wider chemical space than MALDI which is limited by MALDI matrix selection. These ambient ionization techniques are often combined with triple quadrupole, ion trap or time of flight mass spectrometers offering increased sensitivity at the cost of lower spatial resolution.
In a pharmacokinetic study multiple biofluid samples can be taken at required time points post dose, however samples for MSI require the termination of the subject animal and the dissection and sectioning of a target organ. This means that a greater number of animals are required to generate corresponding time course MSI data. Effective cassette dosed MSI experiments would be advantageous with a reduction in both the analytical turnaround time but also the animal handling and husbandry costs. Any significant reduction in the number of animals is advantageous, above and beyond cost savings and analysis time, as it is in keeping with industry wide aims to reduce, reuse and refine experimental animal numbers, the so called '3-Rs'.
The research presented here outlines a novel strategy of mass spectrometry tissue imaging and profiling in routine intravenous and orally cassette dosed pharmacokinetic studies. MSI analysis was not adversely affected by cassette dosing and the tissue distribution data corresponds with the plasma pharmacokinetic (PK) analysis and highlights the advantage of gaining important pharmacokinetic and distribution data from the same animals at an early phase of drug discovery.
Demonstrated for the first time is enhanced tissue profiling technology (LESA) for low spatial resolution imaging. Furthermore, such analysis is combined with near cellular resolution MSI (~20µm) and demonstrates that a suite of instrumentation enables detection of all target compounds and therefore a multi-platform MSI strategy is required for effective pharmaceutical R&D. 
Material and methods

Materials
Animals. Adult male Hans Wistar rats (approximate weight 260g) were obtained from Charles
River Laboratories (Margate, Kent, UK) and were acclimatized on site for a minimum of 3 days prior to dosing. Compounds administered by oral gavage and intravenous bolus injection (via the tail vein) were formulated in 5% dimethylsulfoxide/95% (30% w/v Captisol in water). Control animals were dosed with vehicle via the same administration route in each arm of the study.
Dosing and scheduling. An initial pilot study using intravenous administration consisted of; 1 animal dosed with vehicle, 1 animal dosed discretely with haloperidol (2 mg/kg) and 2 animals were cassette dosed (2 mg/kg/compound, haloperidol, bufuralol, midazolam and clozapine). All intravenously dosed animals were euthanized at 15 minutes post dose.
A more extensive study using oral administration consisted of; 1 animal was dosed with vehicle, 2 animals were dosed discretely with moxifloxacin (25 mg/kg), 2 animals were dosed discretely with olanzapine (10 mg/kg) and 3 animals were cassette dosed (Moxifloxacin, olanzapine, erlotinib and terfenadine at 25, 10, 10 and 25 mg/kg respectively). Blood samples were taken at 0.5, 1, 2, 3, 4 and 5 hrs post dose via the tail vein (0.2 mL) and 6 hrs via cardiac puncture (0.5 mL), the blood was spun at 4500g for 2 mins to yield plasma (approximately 0.1 mL) which was subsequently stored at -20°C prior to analysis. Animals were euthanized at either 2 or 6 hrs post dose.
All tissue dissection was performed by trained AstraZeneca staff (project license 40/3484, procedure number 10). Tissues (brain, kidneys, lungs and liver) were snap-frozen in 2-methylbutane on dry-ice, subsequent transfer of tissues was done on dry-ice and samples were stored at -80 o C until tissue processing.
Tissue processing. Tissue sections were cut at a thickness of 14 μm and thaw mounted onto indium tin oxide (ITO) coated MALDI target slides (Bruker Daltonics, Bremen, Germany) or standard glass microscope slides (VWR, Leicestershire, UK). Sections were taken at approximately equal depth from all organs to allow visualization of similar structures between samples. Organ tissue sections from cassette dosed, discrete dosed and vehicle control animals were mounted adjacent on the same slides to minimize variability caused through variations in 9 matrix application or when analyzing separate MALDI targets. Tissue sections were analyzed randomly and non-sequentially to limit the risk of any observed variation in relative abundance being as a result in loss of analyzer sensitivity during the course of the analysis. Mounted tissue sections, were stored at −80°C until required.
MALDI matrix application. Thaw mounted tissue sections were dried in a stream of nitrogen when removed from -80 o C storage. Optical images were taken using a standard flat bed scanner (Seiko Epson, Negano, Japan) prior to MALDI matrix application. Matrix coating was applied as previously described for the analysis of small molecules using a pneumatic TLC sprayer (Sigma Aldrich) [19] . Either 15 mL of CHCA (10 mg/mL, 50/50 v/v acetonitrile/water, 0.1% TFA) or DHB (70 mg/mL, 50/50 v/v acetonitrile/water, 0.1% TFA) was applied. Following matrix application all subsequent transportation was performed with samples sealed in container to limit effects of light and humidity on sample and matrix. For high spatial resolution, tissue sections were transferred from -80°C to a desiccator and dried for about 30 min prior to matrix coating.
An optical image of the slide was acquired using a flatbed scanner (Epson perfection V500). The tissue was coated with DHB at a lower concentration of 35 mg/ml (50/50 v/v methanol/water, 0.2% TFA) to reflect the more direct application of matrix and to prevent system blockages when using the TM-Sprayer™ Tissue MALDI Sample Preparation System (HTX Technologies, LCC, Carrboro, NC, USA). A flow rate of 80 µL/min, nitrogen pressure 8 psi and a spray nozzle temperature of 95°C was used for 2 passes and 90°C for a subsequent 4 passes of the tissue. PK bioanalysis. Details of the preparation of bioanalytical stock solutions and the bioanalytical method used can be found in the supporting information.
Results and discussion
Obtaining knowledge of the abundance and spatial distribution of compounds in target tissue can be extremely valuable in drug discovery or during a toxicological investigation. An understanding of the distribution profile of candidate drugs can be fed back into project design/make/test cycles, allowing researchers to refine the properties of chemical series early in the drug discovery process. In order to use such distribution information effectively the analysis 13 techniques need to be high throughput while not compromising data quality. This study explores cassette dosing as a viable method of increasing throughput and decreasing the numbers of animals used in distribution studies using mass spectrometry imaging. Data quality was validated by comparing compounds dosed using the cassette approach with compounds that are dosed orally and intravenously as discrete formulations.
Technical replicates were not performed due to instrument time constraints, number of samples involved and the cost of LESA consumables (specifically nanoESI emitters). However, reproducibility of MSI strategies have previously been reported and therefore where not considered to be required for these experiments where relative abundances were measured. If absolute quantitation was performed we would recommend technical replicate analysis to be performed.
Test substance selection. Four compounds were selected for a pilot intravenous cassette dosing experiment. Haloperidol, a dopamine D 2 antagonist, bufuralol, a β-adrenoceptor antagonist and midazolam, a GABA antagonist, were chosen at random, no data about prior MSI analysis has been published to date. Clozapine, a serotonin antagonist that has been used in several in-house studies and is known to be detectable by MALDI-MSI was added to the intravenous cassette to mitigate the risk of failing to detect all compounds in the pilot study by our primary analytical technique.
A further four compounds were selected for a more extensive oral cassette dosing experiment.
Terfenadine, a H 1 receptor antagonist, has been analyzed by MSI following a 50 mg/kg dose (single oral dose) using a hybrid quadrupole-time-of-flight (QqTOF, QStar Pulsar, Applied Biosystems) [20] and at the same dose by LESA profiling (QTRAP 5500, AB Sciex) [13] . Erlotinib, a tyrosine kinase inhibitor, was detected using a hybrid quadrupole-time-of-flight (QqTOF, QStar XL, AB/MDS Sciex)) [21] following 5 mg/kg oral dose. Olanzapine, a dopamine D 2 antagonist was orally dosed at 8 mg/kg and detected using a MALDI time-of-flight (Autoflex, Bruker) [22] . The final compound in the cassette was moxifloxacin, a DNA gyrase inhibitor, detected on a FlashQuant QTRAP (AB Sciex) following oral dose at 25 mg/kg [23] .
Intravenous (IV) dosing.
An initial intravenously dosed pilot study consisting of cassette dosed, discrete dosed and vehicle dosed animals was performed in order to confirm the proof of principle that cassette dosing and discrete dosing show a similar relationship in terms of relative distribution across different tissues. Animals were euthanized at 15 minutes post dose, with brain, kidney, liver and lung samples dissected and snap frozen in 2-methylbutane post mortem.
Distribution of IV dosed compounds by MALDI-MSI. Brain, kidney, liver and lung sections (14 µm) were thaw mounted onto ITO coated microscope slides. Sections were arranged, as stated in the experimental, to minimize intra-analysis variability caused by matrix applications and inter-analysis variability. Typically 3 brain sections representing cassette dosed, discrete dosed and control were mounted on the same slide. Positive ion MALDI-MSI (MALDI Synapt Q-TOF, Waters, Manchester, UK) was employed to analyse brain and liver sections. DHB and CHCA were used as standard MALDI matrices with limited success. Haloperidol, bufuralol and midazolam were not detected with either matrix from either tissue type even though initial ionization testing in the absence of tissue had been positive using both matrices (data not shown).
This poor response could be due to various factors such as ionization suppression from endogenous components and salts in the tissue and could be rectified by using an alternative MALDI matrix, solvent system or by carefully optimized on slide washing of the tissue prior to matrix application [24] and analysis. Clozapine was detected on both tissue types using CHCA as the MALDI matrix, the relative distribution of clozapine at 15 minutes post dose in a sagittal brain section can be seen in figure 1 , normalized by total ion count, at a spatial resolution of 100 µm. Midazolam could not be detected with sufficient mass accuracy (326.0850 Da) from the tissue sections using DESI-MS.
Additional MSI analysis by LESA-MS/MS and DESI
Oral (PO) dosing.
A larger, more comprehensive study was designed to compare cassette dosing to discrete dosing after oral administration. Plasma analysis by LC-MS/MS revealed that cassette and discrete dosed animals were exposed to the test substances in all instances.
Comparative plasma concentrations post dose for moxifloxacin and olanzapine were equivalent in cassette dosed versus discrete dosed animals ( Figure S-1 Erlotinib and terfenadine were distributed in both the cortex and medulla of the kidney, with greater intensity in the medullary region, whereas moxifloxacin and olanzapine were more localized in the medulla of the kidney. The consistent relative abundance between the images for moxifloxacin and olanzapine at each time point for cassette and discrete dosing provides further validation of the cassette dosing approach. Liver and brain sections were also analyzed by MALDI-MSI to confirm detection of the test substances in the various tissue types (data not shown). High spatial resolution MSI is a powerful tool that allows near cellular resolution. The higher spatial resolution images can be used to identify regions of tissue structure within organ tissue sections. Figure 4 shows a high spatial resolution image (20 µm, UltrafleXtreme MALDI-TOF/TOF MS, Bruker Daltonics) of dosed lung section. Olanzapine (m/z 313) represented in green, is distributed throughout the lung tissue, while a blood vessel can be clearly seen in the optical image and is reflected in the MSI image as an area of high heme abundance (m/z 616).
Analysis of orally dosed tissues by
High spatial resolution MSI can highlight distribution of test substances into localized areas of tissue to demonstrate drug presence at the site of action and could be expanded further to confirm target engagement via changes in endogenous disease markers.
Conclusions
Cassette dosing is a widely adopted practice within pharmaceutical discovery research for plasma PK analysis. Here we have demonstrated for the first time its utility in PK tissue distribution studies using mass spectrometry imaging techniques. Cassette dosing fundamentally increases throughput, in this case by four-fold, greatly reducing what has traditionally been an analytical bottleneck. The combination of cassette dosed PK and drug distribution studies have many advantages; ethically the technique reduces the number of animals used, typically by around 75%; the combination also leads to a wealth of pharmacokinetic and distribution data being available at a much earlier stage of drug discovery and can lead to a much greater 20 confidence that compounds are present at the pharmacological site of action. It is also possible to measure and monitor compound abundance target tissue in response to dose or time.
Mass spectrometry imaging covers a variety of relatively new and exciting technologies that can be used to study the regional abundance of xenobiotics within tissues, while also simultaneously measuring endogenous molecules. A single technique is yet to emerge that can successfully analyse the full scope of chemistries encountered in drug discovery, at sufficient sensitivity and with high spatial resolution. MALDI-MSI was successfully used to analyse orally cassette dosed tissue sections at 100 µm and at higher spatial resolution (15 µm). LESA-MS/MS was validated against the MALDI-MSI data. The success of MALDI-MSI to analyse the compounds in the oral cassette dosed study was contrasted against an intravenously dosed cassette study in which the technique had less success. LESA-MS/MS and DESI-MS were used to profile the relative distribution of the intravenously dosed compounds, at lower spatial resolution, but with a higher success rate.
The cassette dosing strategy has been shown to be a successful approach to obtain early, combined pharmacokinetic and distribution data. Mass spectrometric imaging techniques have an increasingly important role to play in pharmaceutical R&D, with techniques being developed to provide more quantitative data and the expansion of MALDI-MSI, in particular, into areas of targeted and untargeted metabolomics.
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